Hunan University of Chinese Medicine

Over the last two decades, bioelectrical impedance analysis (BIA) has gained popularity as a method for assessing body compartments in nutrition studies, sports medicine, and evaluating hydration levels, fat mass, and fat-free mass variations in both healthy and diseased individuals. This study aims to offer researchers an overview of the research trends in BIA.

The data was obtained from the Web of Science Core Collection database. Bibliometric analysis was conducted using a package of R software (Bibliometrix 4.0).

A total of 9471 articles have been published over the past 20 years, with an average annual growth rate of 10.1%. The research field primarily focuses on nutrition and dietetics, followed urology and nephrology, endocrinology and metabolism, general and internal medicine, engineering, geriatrics and gerontology, sport sciences, cardiovascular system and cardiology, physiology and science and technology-other topics. The research hotspots of BIA over the past 20 years have transitioned from "water" to "fat," and subsequently to "sarcopenia." "Sarcopenia" and "phase angle" (PhA) have emerged as recent research hotspots in the field of BIA.

A total of 9471 articles have been published over the past 20 years, with an average annual growth rate of 10.1%. Nutrition and dietetics have consistently been the primary research areas in the field of BIA. "Sarcopenia" and "PhA" have emerged as recent research hotspots in the field of BIA. The application of BIA in clinical practice still holds significant untapped potential.

The association between dietary energy intake and disease outcomes in CKD 3-5 remains unclear. This study explored this relationship in Southern Chinese CKD 3-5 patients.

This retrospective cohort study included 234 CKD 3-5 patients from the Self-Management Program for Patients with Chronic Kidney Disease (SMP-CKD) database. The endpoint was a composite of sustained decline of at least 30% in estimated glomerular filtration rate (eGFR), the initiation of kidney replacement therapy, or all-cause mortality. The main variable was energy intake. Kaplan-Meier analysis, restricted cubic splines, and Cox regression models were performed to assess the association.

85 (36.3%) individuals reached the endpoint with a median follow-up of 33 months. The median age was 56.0 (46.3, 63.3) years, and 121 (51.7%) were male. The association between energy intake and the endpoint in CKD 3-5 patients showed a U-shaped relationship. We reclassified patients according to energy intake: Group 1 (<24.6 kcal/kg/d), Group 2 (24.6-29.5 kcal/kg/d), and Group 3 (>29.5 kcal/kg/d). Compared to Group 2, Group 3 (HR = 3.0; 95%CI, 1.118-7.993, p = 0.029) and Group 1 (HR = 2.5; 95%CI, 1.068-5.966, p = 0.035) had a higher risk of reaching the endpoint. Subgroup analysis showed no significant interaction except for age, with a consistent U-shaped relationship in those ≤ 60 years.

High and low energy intake are significantly associated with an increased risk of adverse outcomes in non-dialysis CKD 3-5 patients. An energy intake of 24.6-29.5 kcal/kg/day may be optimal to reduce the risk of poor health outcomes.

Liver cancer is a common malignancy in the world, and its incidence and mortality rate are increasing year by year. The disease has a short course and a high mortality rate, posing a serious threat to humanity and health. The objective of this study is to create novel liver-targeted nanoparticles as a potential treatment for liver cancer. The aptamer (APS613-1) modified redox-sensitive norcantharidin solid lipid nanoparticles (Apt-PEG₂₀₀₀-ss-NCTD-SLNs) were prepared by emulsified ultrasonic dispersion method and characterized. The tumor targeting, antitumor effect and safety of the nanoparticles were investigated and evaluated in vitro and in vivo. The particle size of Apt-PEG₂₀₀₀-ss-NCTD-SLNs was 87.95 ± 3.32 nm, and the encapsulation efficiency was about 80.74 ± 2.36%, which had good biocompatibility. The results of in vitro experiments showed that, compared with unmodified solid lipid nanoparticles (NCTD-SLNs), Apt-PEG_2000-ss-NCTD-SLNs had better targeting for liver tumor cells, and a stronger ability to inhibit cell proliferation and migration, as well as promote cell apoptosis. The in vivo results revealed that Apt-PEG₂₀₀₀-ss-NCTD-SLNs demonstrated good safety and anti-tumor efficacy, and its mechanism was achieved through the inhibition of cell proliferation and induction of apoptosis. The functionalized nanoparticles modified by aptamer APS613-1 can be used for the liver-targeted delivery of antitumor drugs for the treatment of liver cancer, and Apt-PEG₂₀₀₀-ss-NCTD-SLN is a potential drug for the treatment of liver cancer.